Laura Gault - 13 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Medical Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Laura Gault
Issuer symbol
SAGE
Transactions as of
13 Feb 2023
Net transactions value
$0
Form type
4
Filing time
15 Feb 2023, 15:47:19 UTC
Previous filing
01 Nov 2022
Next filing
15 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +2,660 $0.000000 2,660 13 Feb 2023 Common Stock 2,660 $45.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 665 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 1,995 shares vesting in 36 equal monthly installments thereafter.